The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer.
Himisha Beltran
Research Funding - Millennium
Mark A. Rubin
No relevant relationships to disclose
Juan Miguel Mosquera
No relevant relationships to disclose
Paul J. Christos
No relevant relationships to disclose
Olivera Calukovic
No relevant relationships to disclose
Irene Karpenko
No relevant relationships to disclose
Jacek K. Pinski
No relevant relationships to disclose
Daniel Costin Danila
No relevant relationships to disclose
David M. Nanus
No relevant relationships to disclose
Scott T. Tagawa
No relevant relationships to disclose